Cargando…

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy

Over the past decade, theranostic imaging has emerged as a powerful clinical tool in oncology for identifying patients likely to respond to targeted therapies and for monitoring the response of patients to treatment. Herein, we report a theranostic approach to pretargeted radioimmunotherapy (PRIT) b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keinänen, Outi, Fung, Kimberly, Brennan, James M., Zia, Nicholas, Harris, Matt, van Dam, Ellen, Biggin, Colin, Hedt, Amos, Stoner, Jon, Donnelly, Paul S., Lewis, Jason S., Zeglis, Brian M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2020
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668034/ https://www.ncbi.nlm.nih.gov/pubmed/33106429 http://dx.doi.org/10.1073/pnas.2009960117

Ejemplares similares

Pretargeted Molecular Imaging and Radioimmunotherapy
por: Goldenberg, David M., et al.
Publicado: (2012)

Improvement of Radioimmunotherapy Using Pretargeting
por: Frampas, Eric, et al.
Publicado: (2013)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

Pretargeting of internalizing trastuzumab and cetuximab with a (18)F-tetrazine tracer in xenograft models
por: Keinänen, Outi, et al.
Publicado: (2017)

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer
por: Kraeber–Bodéré, F., et al.
Publicado: (2009)

A pretargeting system for tumor PET imaging and radioimmunotherapy
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

Theragnostic (64)Cu/(67)Cu Radioisotopes Production With RFT-30 Cyclotron
por: Lee, Jun Young, et al.
Publicado: (2022)

Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry
por: van de Watering, Floor C. J., et al.
Publicado: (2014)

Cyclotron-Based Production of (67)Cu for Radionuclide Theranostics via the (70)Zn(p,α)(67)Cu Reaction
por: Brühlmann, Santiago Andrés, et al.
Publicado: (2023)

Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma
por: Cheal, Sarah M., et al.
Publicado: (2018)

An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [(64/67)Cu]Cu-SARTATE
por: Laffon, Eric, et al.
Publicado: (2021)

Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept
por: Rondon, Aurélie, et al.
Publicado: (2019)

Cyclotron-based production of the theranostic radionuclides $^{67}$Cu and $^{47}$Sc
por: Pupillo, G, et al.
Publicado: (2019)

Detection and therapy of neuroblastoma minimal residual disease using [(64/67)Cu]Cu-SARTATE in a preclinical model of hepatic metastases
por: Dearling, Jason L. J., et al.
Publicado: (2021)

Development of an automated production process of [(64)Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications
por: Liu, Tengzhi, et al.
Publicado: (2022)

In vitro and in vivo characterization of [(64)Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors
por: Liu, Tengzhi, et al.
Publicado: (2023)

Pretargeted Nuclear Imaging and Radioimmunotherapy Based on the Inverse Electron-Demand Diels–Alder Reaction and Key Factors in the Pretargeted Synthetic Design
por: Qiu, Lin, et al.
Publicado: (2019)

Evaluation of [(64)Cu]Cu-NOTA-PEG(7)-H-Tz for Pretargeted Imaging in LS174T Xenografts—Comparison to [(111)In]In-DOTA-PEG(11)-BisPy-Tz
por: Poulie, Christian B. M., et al.
Publicado: (2021)

Hypoxia imaging and theranostic potential of [(64)Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms
por: Liu, Tengzhi, et al.
Publicado: (2020)

Theragnostic Radionuclide Pairs for Prostate Cancer Management: (64)Cu/(67)Cu, Can Be a Budding Hot Duo
por: Chhabra, Anupriya, et al.
Publicado: (2022)

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

Harnessing PET to track micro- and nanoplastics in vivo
por: Keinänen, Outi, et al.
Publicado: (2021)

Radiobiological Characterization of (64)CuCl(2) as a Simple Tool for Prostate Cancer Theranostics
por: Guerreiro, Joana Fernandes, et al.
Publicado: (2018)

Potential Production of Theranostic Boron Nitride Nanotubes ((64)Cu-BNNTs) Radiolabeled by Neutron Capture
por: Silva, Wellington Marcos, et al.
Publicado: (2021)

Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study
por: Grana, C, et al.
Publicado: (2002)

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients
por: Bodet-Milin, Caroline, et al.
Publicado: (2015)

Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy
por: Woliner-van der Weg, Wietske, et al.
Publicado: (2015)

Biokinetic and dosimetric aspects of (64)CuCl(2) in human prostate cancer: possible theranostic implications
por: Righi, Sergio, et al.
Publicado: (2018)

Preclinical Evaluation of a (64)Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma
por: Métivier, Cassandra, et al.
Publicado: (2023)

Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine
por: Hapuarachchige, Sudath, et al.
Publicado: (2020)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model
por: Ullrich, Martin, et al.
Publicado: (2016)

Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT(R))
por: De Santis, R, et al.
Publicado: (2003)

Is (70)Zn(d,x)(67)Cu the Best Way to Produce (67)Cu for Medical Applications?
por: Nigron, Etienne, et al.
Publicado: (2021)

Theranostic (64)Cu-DOTHA(2)-PSMA allows low toxicity radioligand therapy in mice prostate cancer model
por: Milot, Marie-Christine, et al.
Publicado: (2023)

[(64)Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans
por: Jensen, Jacob K., et al.
Publicado: (2022)

Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models
por: Frost, Sofia H. L., et al.
Publicado: (2015)

Pretargeted PET Imaging of trans-Cyclooctene-Modified Porous Silicon Nanoparticles
por: Keinänen, Outi, et al.
Publicado: (2017)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kvr3huadc1feenr4i9u5ummsir